Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,666,684
  • Shares Outstanding, K 101,122
  • Annual Sales, $ 0 K
  • Annual Income, $ -408,170 K
  • EBIT $ -849 M
  • EBITDA $ -842 M
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.77

Options Overview Details

View History
  • Implied Volatility 75.91% ( -13.21%)
  • Historical Volatility 60.37%
  • IV Percentile 43%
  • IV Rank 26.27%
  • IV High 138.64% on 05/24/24
  • IV Low 53.57% on 08/16/24
  • Put/Call Vol Ratio 1.93
  • Today's Volume 3,205
  • Volume Avg (30-Day) 910
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 37,278
  • Open Int (30-Day) 35,134

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.53
  • Number of Estimates 9
  • High Estimate -0.56
  • Low Estimate -2.01
  • Prior Year -1.81
  • Growth Rate Est. (year over year) +15.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.46 +5.22%
on 12/20/24
47.75 -24.06%
on 11/27/24
-10.57 (-22.57%)
since 11/20/24
3-Month
34.46 +5.22%
on 12/20/24
55.70 -34.90%
on 10/08/24
-4.13 (-10.23%)
since 09/20/24
52-Week
26.80 +35.30%
on 05/29/24
62.21 -41.71%
on 03/08/24
-1.66 (-4.38%)
since 12/20/23

Most Recent Stories

More News
Biohaven’s SMA Trial Miss Bolsters Scholar Rock Stock: Analysts Give Verdicts, Retail Watches Closely

Last month, Scholar Rock achieved the primary endpoint in the company's own Phase 3 trial of apitegromab in SMA patients.

BHVN : 36.26 (+2.60%)
VTI : 293.28 (+1.14%)
SRRK : 44.78 (+6.39%)
IWM : 221.92 (+0.94%)
XBI : 91.28 (+1.64%)
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 36.26 (+2.60%)
ANIP : 53.35 (-1.68%)
CPRX : 21.27 (-0.89%)
SRRK : 44.78 (+6.39%)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for...

BHVN : 36.26 (+2.60%)
KRYS : 164.83 (+2.49%)
FULC : 4.35 (+7.94%)
ANIP : 53.35 (-1.68%)
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

BHVN : 36.26 (+2.60%)
Canada Jobs in Focus Next Week

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

VRTX : 397.27 (+0.16%)
MCHP : 55.51 (-0.86%)
PLTR : 80.55 (+8.54%)
DIS : 112.03 (+0.59%)
ANET : 112.81 (+3.43%)
TM : 178.17 (+2.27%)
UBER : 60.73 (+0.86%)
ABNB : 134.21 (+3.76%)
HMC : 23.89 (+0.80%)
CEG : 227.02 (+0.82%)
RBLX : 60.11 (+2.04%)
BHVN : 36.26 (+2.60%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 36.26 (+2.60%)
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 36.26 (+2.60%)
Markets Today: Stocks Decline as Bond Yields Soar

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.61%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.76%. Stock index futures this morning are moderately lower, weighed...

ESH25 : 6,001.75s (+1.14%)
NQH25 : 21,566.50s (+0.88%)
MCK : 579.74 (+0.09%)
BHVN : 36.26 (+2.60%)
ABNB : 134.21 (+3.76%)
KLG : 17.92 (+0.22%)
HPQ : 32.94 (+1.48%)
DOW : 39.94 (+2.15%)
LYB : 73.50 (+0.73%)
FVRR : 32.28 (+0.88%)
DY : 173.76 (+2.57%)
PNT : 12.50 (+0.16%)
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 36.26 (+2.60%)
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 36.26 (+2.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut....

See More

Key Turning Points

3rd Resistance Point 39.81
2nd Resistance Point 38.38
1st Resistance Point 37.32
Last Price 36.26
1st Support Level 34.83
2nd Support Level 33.40
3rd Support Level 32.34

See More

52-Week High 62.21
Fibonacci 61.8% 48.68
Fibonacci 50% 44.50
Fibonacci 38.2% 40.33
Last Price 36.26
52-Week Low 26.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar